RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - March 28, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company has received regulatory clearance from Health Canada to convert the dosing schedule of its Phase II study of single agent ADH-1 to once every week from once every three weeks. Adherex is also adding clinical trial sites in the U.S. The trial is being performed at six centers in Canada.
